Mast Cell Inhibition for Diverse Applications Beyond BPH/LUTS

Publication ID: 24-11857531_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Mast Cell Inhibition for Diverse Applications Beyond BPH/LUTS,” Published Technical Disclosure No. 24-11857531_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857531_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,531.

Summary of the Inventive Concept

This inventive concept leverages the core technology of mast cell inhibition to address unmet needs in agriculture, environmental sustainability, aquaculture, veterinary medicine, and human skin health, demonstrating its versatility and broad applicability.

Background and Problem Solved

The original patent focused on treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) using mast cell inhibition. However, the potential of this technology extends far beyond these specific applications. This inventive concept tackles the limitations of the original patent by exploring new use cases and industries where mast cell inhibition can provide significant benefits.

Detailed Description of the Inventive Concept

The new claims showcase the adaptability of mast cell inhibition in various contexts. For instance, in agriculture, mast cell stabilizers and histamine receptor antagonists can be used to prevent histamine release in response to pest allergens, reducing crop damage. In environmental sustainability, mast cell inhibitors and histamine receptor antagonists can mitigate the effects of climate change on pollinator populations. Similarly, in aquaculture, this composition can reduce inflammation and improve water quality. In veterinary medicine, the system can treat respiratory diseases in companion animals, and in human skin health, topical compositions can reduce inflammation and improve skin barrier function.

Novelty and Inventive Step

The novelty of this inventive concept lies in its application of mast cell inhibition to entirely new industries and problem domains. The inventive step is the recognition of the broader potential of this technology and its adaptation to address unmet needs in diverse fields.

Alternative Embodiments and Variations

Alternative embodiments of this inventive concept could include using different types of mast cell inhibitors or histamine receptor antagonists, varying the composition or dosage, or exploring other modes of administration. Additionally, the concept could be extended to other industries or applications, such as cosmetics, textiles, or biotechnology.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential across multiple industries, including agriculture, environmental sustainability, aquaculture, veterinary medicine, and human skin health. The market for these applications is substantial, with potential revenue streams from product sales, licensing, and partnerships.

Field of Art

Pharmacological and medical research focusing on mast cell inhibition, inflammation management, and cross-domain therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in pharmacology, biochemistry, or biomedical engineering, possessing expertise in inflammatory response mechanisms, drug repurposing, and interdisciplinary therapeutic applications

Obviousness Rationale

A PHOSITA would recognize that mast cell inhibition and histamine receptor antagonism represent fundamental mechanisms of inflammatory control that can be systematically applied across diverse biological systems. The source patent's core methodology of using mast cell inhibitors and histamine receptor antagonists provides a clear technological framework for addressing inflammatory responses in multiple contexts. The PTD's variations represent predictable extensions of this foundational approach by applying known pharmacological principles to different domains with similar underlying physiological challenges.

Obvious Combinations & Variations

Source Patent Element
Mast cell inhibition using cromolyn sodium and cetirizine for treating BPH/LUTS
PTD Variation
Agricultural pest control using mast cell stabilizers to prevent histamine-mediated allergic responses
Obviousness Reasoning
A PHOSITA would recognize that inflammatory mechanisms are fundamentally similar across biological systems, and mast cell stabilization represents a known technique for modulating immune responses in diverse contexts
Source Patent Element
Combination therapy targeting inflammatory pathways
PTD Variation
Aquaculture inflammation reduction using mast cell inhibitors
Obviousness Reasoning
The predictable application of anti-inflammatory pharmaceutical strategies to different biological environments represents a standard approach for addressing systemic inflammatory challenges
Source Patent Element
Histamine receptor antagonism in human medical treatment
PTD Variation
Veterinary respiratory disease treatment using similar pharmacological mechanisms
Obviousness Reasoning
Cross-species application of inflammatory control mechanisms is a well-established pharmaceutical research strategy with predictable translational potential
Source Patent Element
Targeting mast cell function to manage physiological symptoms
PTD Variation
Topical skin health compositions using mast cell inhibitors
Obviousness Reasoning
Extending inflammatory management techniques to dermatological applications represents a logical and foreseeable innovation within standard pharmaceutical research paradigms
Source Patent Element
Combination pharmaceutical approach targeting inflammatory pathways
PTD Variation
Climate change mitigation for pollinator populations through inflammatory response management
Obviousness Reasoning
Applying known pharmacological intervention strategies to environmental conservation represents a predictable extension of existing scientific knowledge
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857531, a person having ordinary skill in the art would find the variations disclosed in the Published Technical Disclosure to represent obvious modifications of the foundational mast cell inhibition methodology. The systematic application of established inflammatory control mechanisms across diverse domains demonstrates that the claimed innovations would have been obvious to a skilled practitioner at the time of invention, thereby anticipating and rendering obvious subsequent patent claims with substantially similar technical approaches.

Original Patent Information

Patent NumberUS 11,857,531
TitleCombination mast cell inhibition for treatment of BPH/LUTS
Assignee(s)Northwestern University